1
|
Langan EA. Prolactin: A Mammalian Stress Hormone and Its Role in Cutaneous Pathophysiology. Int J Mol Sci 2024; 25:7100. [PMID: 39000207 PMCID: PMC11241005 DOI: 10.3390/ijms25137100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2024] [Revised: 06/20/2024] [Accepted: 06/20/2024] [Indexed: 07/16/2024] Open
Abstract
The hormone prolactin (PRL) is best recognised for its indispensable role in mammalian biology, specifically the regulation of lactation. Bearing in mind that the mammary gland is a modified sweat gland, it is perhaps unsurprising to discover that PRL also plays a significant role in cutaneous biology and is implicated in the pathogenesis of a range of skin diseases, often those reportedly triggered and/or exacerbated by psychological stress. Given that PRL has been implicated in over 300 biological processes, spanning reproduction and hair growth and thermo- to immunoregulation, a comprehensive understanding of the relationship between PRL and the skin remains frustratingly elusive. In an historical curiosity, the first hint that PRL could affect skin biology came from the observation of seborrhoea in patients with post-encephalitic Parkinsonism as a result of another global pandemic, encephalitis lethargica, at the beginning of the last century. As PRL is now being postulated as a potential immunomodulator for COVID-19 infection, it is perhaps timeous to re-examine this pluripotent hormone with cytokine-like properties in the cutaneous context, drawing together our understanding of the role of PRL in skin disease to illustrate how targeting PRL-mediated signalling may represent a novel strategy to treat a range of skin diseases and hair disorders.
Collapse
Affiliation(s)
- Ewan A. Langan
- Department of Dermatology, University of Luebeck, Ratzeburger Allee 160, 23562 Luebeck, Germany;
- Dermatological Sciences, University of Manchester, Oxford Rd, Manchester M13 9PL, UK
| |
Collapse
|
2
|
Lee J, Ryu HJ, Hwang SY, Koh SB. Hair Loss: A Well-Known Yet Understudied Symptom in Parkinson's Disease Patients During Dopaminergic Therapy. J Mov Disord 2024; 17:47-54. [PMID: 37748925 PMCID: PMC10846976 DOI: 10.14802/jmd.23088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2023] [Revised: 07/18/2023] [Accepted: 09/24/2023] [Indexed: 09/27/2023] Open
Abstract
OBJECTIVE Hair loss has been reported to occur during dopaminergic therapy in patients with Parkinson's disease. The mechanism by which dopaminergic therapy induces hair loss is not well understood. Dopamine receptors are present in the hair follicle, where they regulate melanin production. However, the role of dopamine receptors in hair growth is still not well understood. This study aimed to evaluate the prevalence of hair loss and identify factors associated with complaints of hair loss in patients with Parkinson's disease. METHODS A cross-sectional design involving 495 Parkinson's disease patients was applied to evaluate hair loss status. Patients completed a questionnaire, and scalp/hair examinations were performed. Patients with underlying conditions that could affect hair loss and those prescribed medications known to increase the risk of hair loss were excluded. Finally, 291 patients (58.8%) were included for analysis. RESULTS Among the 495 patients, 138 (27.9%) reported hair loss. Interestingly, more than half of the patients who complained of hair loss (79 out of 138) did not utilize treatments such as hair products, massage, dietary modifications, or alopecia medications. Hair inspection by a single investigator revealed objective hair loss in 263 patients (53.1%). An analysis of factors associated with hair loss complaints showed that the intake of dopaminergic medications with a levodopa-equivalent daily dose > 448 mg was associated with complaints of hair loss. CONCLUSION Dopaminergic medication is associated with hair loss complaints in Parkinson's disease patients.
Collapse
Affiliation(s)
- Jungyeun Lee
- Department of Neurology and Parkinson’s Disease Center, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
| | - Hwa Jung Ryu
- Department of Dermatology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea
| | - Soon Young Hwang
- Department of Biostatistics, Korea University College of Medicine, Seoul, Korea
| | - Seong-Beom Koh
- Department of Neurology and Parkinson’s Disease Center, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
| |
Collapse
|
3
|
Hawkshaw N, Hardman J, Alam M, Jimenez F, Paus R. Deciphering the molecular morphology of the human hair cycle: Wnt signalling during the telogen–anagen transformation. Br J Dermatol 2019; 182:1184-1193. [DOI: 10.1111/bjd.18356] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/12/2019] [Indexed: 12/24/2022]
Affiliation(s)
- N.J. Hawkshaw
- Centre for Dermatology Research The University of Manchester and NIHR Biomedical Research Centre Manchester U.K
| | - J.A. Hardman
- Centre for Dermatology Research The University of Manchester and NIHR Biomedical Research Centre Manchester U.K
| | - M. Alam
- Mediteknia Skin and Hair Lab Las Palmas de Gran Canaria Spain
- Monasterium Laboratory Skin and Hair Research Solutions GmbH Münster Germany
- Universidad Fernando Pessoa‐Canarias Las Palmas de Gran Canaria Spain
| | - F. Jimenez
- Mediteknia Skin and Hair Lab Las Palmas de Gran Canaria Spain
- Universidad Fernando Pessoa‐Canarias Las Palmas de Gran Canaria Spain
| | - R. Paus
- Centre for Dermatology Research The University of Manchester and NIHR Biomedical Research Centre Manchester U.K
- Monasterium Laboratory Skin and Hair Research Solutions GmbH Münster Germany
- Dr Phillip Frost Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine Miami FL U.S.A
| |
Collapse
|
4
|
Langan EA, Fink T, Paus R. Is prolactin a negative neuroendocrine regulator of human skin re-epithelisation after wounding? Arch Dermatol Res 2018; 310:833-841. [PMID: 30244404 DOI: 10.1007/s00403-018-1864-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Revised: 08/27/2018] [Accepted: 09/03/2018] [Indexed: 12/29/2022]
Abstract
Chronic wounds remain a major unmet healthcare challenge, associated with substantial morbidity and economic costs. Therefore, novel treatment strategies and therapeutic approaches need to be urgently developed. Yet, despite the increasingly recognized importance of neurohormonal signaling in skin physiology, the neuroendocrine regulation of cutaneous wound healing has received surprisingly little attention. Human skin, and its appendages, locally express the pleiotropic neurohormone prolactin (PRL), which not only regulates lactation but also hair follicle cycling, angiogenesis, keratinocyte proliferation, and epithelial stem cell functions. Therefore, we examined the effects of PRL in experimentally wounded female human skin organ culture. Overall, this revealed that PRL slightly, but significantly, inhibited epidermal regeneration (reepithelialisation), cytokeratin 6 protein expression and intraepidermal mitochondrial activity (MTCO1 expression), while it promoted keratinocyte terminal differentiation (i.e. involucrin expression) ex vivo. If the current pilot data are confirmed by further studies, PRL may serve as one of the-rarely studied-negative regulators of cutaneous wound healing that control excessive reepithelialisation. This raises the intriguing and clinically relevant question of whether PRL receptor antagonists could actually promote epidermal repair after human skin wounding.
Collapse
Affiliation(s)
- E A Langan
- Department of Dermatology, University of Luebeck, Luebeck, Germany.,Centre for Dermatology Research, University of Manchester, Manchester, UK
| | - T Fink
- Department of Dermatology, Klinikum Oldenburg, Oldenburg, Germany
| | - R Paus
- Centre for Dermatology Research, University of Manchester, Manchester, UK. .,Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
| |
Collapse
|
5
|
Langan EA, Hinde E, Paus R. Prolactin as a candidate sebotrop(h)ic hormone? Exp Dermatol 2018; 27:729-736. [DOI: 10.1111/exd.13545] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/20/2018] [Indexed: 12/11/2022]
Affiliation(s)
- Ewan A. Langan
- Department of Dermatology; University of Luebeck; Luebeck Germany
- Dermatology Research Centre; NIHR Manchester Biomedical Research Centre; University of Manchester; Manchester UK
| | - Eleanor Hinde
- Dermatology Research Centre; NIHR Manchester Biomedical Research Centre; University of Manchester; Manchester UK
| | - Ralf Paus
- Dermatology Research Centre; NIHR Manchester Biomedical Research Centre; University of Manchester; Manchester UK
- Department of Dermatology and Cutaneous Surgery; University of Miami Miller School of Medicine; Miami FL USA
| |
Collapse
|
6
|
Paus R. Exploring the “brain-skin connection”: Leads and lessons from the hair follicle. Curr Res Transl Med 2016; 64:207-214. [DOI: 10.1016/j.retram.2016.10.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Accepted: 10/14/2016] [Indexed: 12/22/2022]
|
7
|
Harvey S, Martínez-Moreno CG, Luna M, Arámburo C. Autocrine/paracrine roles of extrapituitary growth hormone and prolactin in health and disease: An overview. Gen Comp Endocrinol 2015; 220:103-11. [PMID: 25448258 DOI: 10.1016/j.ygcen.2014.11.004] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/04/2014] [Accepted: 11/03/2014] [Indexed: 02/07/2023]
Abstract
Growth hormone (GH) and prolactin (PRL) are both endocrines that are synthesized and released from the pituitary gland into systemic circulation. Both are therefore hormones and both have numerous physiological roles mediated through a myriad of target sites and both have pathophysiological consequences when present in excess or deficiency. GH or PRL gene expression is not, however, confined to the anterior pituitary gland and it occurs widely in many of their central and peripheral sites of action. This may reflect "leaky gene" phenomena and the fact that all cells have the potential to express every gene that is present in their genome. However, the presence of GH or PRL receptors in these extrapituitary sites of GH and PRL production suggests that they are autocrine or paracrine sites of GH and PRL action. These local actions often occur prior to the ontogeny of pituitary somatotrophs and lactotrophs and they may complement or differ from the roles of their pituitary counterparts. Many of these local actions are also of physiological significance, since they are impaired by a blockade of local GH or PRL production or by an antagonism of local GH or PRL action. These local actions may also be of pathophysiological significance, since autocrine or paracrine actions of GH and PRL are thought to be causally involved in a number of disease states, particularly in cancer. Autocrine GH for instance, is thought to be more oncogenic than pituitary GH and selective targeting of the autocrine moiety may provide a therapeutic approach to prevent tumor progression. In summary, GH and PRL are not just endocrine hormones, as they have autocrine and/or paracrine roles in health and disease.
Collapse
Affiliation(s)
- Steve Harvey
- Department of Physiology, University of Alberta, Edmonton T6G 2H7, Canada.
| | | | - Maricela Luna
- Departamento de Neurobiología, Celular y Molecular Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, Qro. 76230, Mexico
| | - Carlos Arámburo
- Departamento de Neurobiología, Celular y Molecular Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, Qro. 76230, Mexico
| |
Collapse
|
8
|
Paus R, Langan EA, Vidali S, Ramot Y, Andersen B. Neuroendocrinology of the hair follicle: principles and clinical perspectives. Trends Mol Med 2014; 20:559-70. [DOI: 10.1016/j.molmed.2014.06.002] [Citation(s) in RCA: 85] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2014] [Revised: 06/09/2014] [Accepted: 06/12/2014] [Indexed: 12/16/2022]
|
9
|
Ramot Y, Paus R. Harnessing neuroendocrine controls of keratin expression: A new therapeutic strategy for skin diseases? Bioessays 2014; 36:672-86. [DOI: 10.1002/bies.201400006] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Yuval Ramot
- Department of Dermatology; Hadassah - Hebrew University Medical Center; Jerusalem Israel
| | - Ralf Paus
- Dermatology Research Centre; Institute of Inflammation and Repair; University of Manchester; Manchester UK
- Laboratory for Hair Research and Regenerative Medicine, Department of Dermatology; University of Münster; Münster Germany
| |
Collapse
|
10
|
Langan EA, Vidali S, Pigat N, Funk W, Lisztes E, Bíró T, Goffin V, Griffiths CEM, Paus R. Tumour necrosis factor alpha, interferon gamma and substance P are novel modulators of extrapituitary prolactin expression in human skin. PLoS One 2013; 8:e60819. [PMID: 23626671 PMCID: PMC3634033 DOI: 10.1371/journal.pone.0060819] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2012] [Accepted: 03/03/2013] [Indexed: 12/31/2022] Open
Abstract
Human scalp skin and hair follicles (HFs) are extra-pituitary sources of prolactin (PRL). However, the intracutaneous regulation of PRL remains poorly understood. Therefore we investigated whether well-recognized regulators of pituitary PRL expression, which also impact on human skin physiology and pathology, regulate expression of PRL and its receptor (PRLR) in situ. This was studied in serum-free organ cultures of microdissected human scalp HFs and skin, i.e. excluding pituitary, neural and vascular inputs. Prolactin expression was confirmed at the gene and protein level in human truncal skin, where its expression significantly increased (p = 0.049) during organ culture. There was, however, no evidence of PRL secretion into the culture medium as measured by ELISA. PRL immunoreactivity (IR) in female human epidermis was decreased by substance P (p = 0.009), while neither the classical pituitary PRL inhibitor, dopamine, nor corticotropin-releasing hormone significantly modulated PRL IR in HFs or skin respectively. Interferon (IFN) γ increased PRL IR in the epithelium of human HFs (p = 0.044) while tumour necrosis factor (TNF) α decreased both PRL and PRLR IR. This study identifies substance P, TNFα and IFNγ as novel modulators of PRL and PRLR expression in human skin, and suggests that intracutaneous PRL expression is not under dopaminergic control. Given the importance of PRL in human hair growth regulation and its possible role in the pathogenesis of several common skin diseases, targeting intracutaneous PRL production via these newly identified regulatory pathways may point towards novel therapeutic options for inflammatory dermatoses.
Collapse
Affiliation(s)
- Ewan A. Langan
- Dermatology Research Centre, Manchester Academic Health Science Centre, and Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom
- Department of Dermatology, University of Lübeck, Lübeck, Germany
| | - Silvia Vidali
- Department of Dermatology, University of Lübeck, Lübeck, Germany
| | - Natascha Pigat
- Inserm U845/Centre de Recherche Croissance et Signalisation, Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | | | - Erika Lisztes
- DE-MTA “Lendület” Cellular Physiology Research Group, Department of Physiology, University of Debrecen, Debrecen, Hungary
| | - Tamás Bíró
- DE-MTA “Lendület” Cellular Physiology Research Group, Department of Physiology, University of Debrecen, Debrecen, Hungary
| | - Vincent Goffin
- Inserm U845/Centre de Recherche Croissance et Signalisation, Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Christopher E. M. Griffiths
- Dermatology Research Centre, Manchester Academic Health Science Centre, and Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom
| | - Ralf Paus
- Dermatology Research Centre, Manchester Academic Health Science Centre, and Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom
- Department of Dermatology, University of Lübeck, Lübeck, Germany
- * E-mail:
| |
Collapse
|